Phaseline

Companies › Hasten Biopharmaceutical

Hasten Biopharmaceutical: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Metabolic and endocrine.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Lerodalcibep (HST101)
Subtilisin/kexin type 9 inhibitor
PCSK9Phase 3Hypercholesterolemia–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06568471Lerodalcibep (HST101)Phase 3HypercholesterolemiaMetabolic and endocrineFeb 2026

Targets

PCSK9 (1)

Companies with the same targets

Novartis AstraZeneca NewAmsterdam Pharma Verve Therapeutics Amgen Merck & Co. (MSD) Innovent Biologics (Suzhou) Regeneron Pharmaceuticals

Companies built like this

BrightGene New Bio-Medical Technology(Wuxi) Co.Ltd. Xintian Pharmaceutical Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics Orphalan Lumos Pharma

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.